First Tracks Biotherapeutics Inc
TRAX | NASDAQ
$45.99
+$0.91 (+2.02%)
Nov 2, 2026, 9:52 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 |
|---|---|---|---|
Revenue | n/a | n/a | n/a |
Cost of Revenue | 139.61M | 152.35M | n/a |
Gross Profit | -139.61M | -152.35M | n/a |
Operating Income | -179.01M | -181.1M | -118.46M |
Interest Income | 12.94M | 17.38M | 12.31M |
Pretax Income | -166.09M | -163.71M | -106.15M |
Net Income | -166.09M | -163.71M | -106.15M |
Selling & General & Admin | 39.39M | 28.76M | 20.87M |
Research & Development | 139.61M | 152.35M | 97.59M |
Other Expenses | -139.61M | -152.35M | n/a |
Operating Expenses | 39.39M | 28.76M | 118.46M |
Interest Expense | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a |
Cost & Expenses | 179.01M | 181.1M | 118.46M |
Income Tax Expense | n/a | n/a | n/a |
Shares Outstanding (Basic) | 34.75M | 34.75M | 34.75M |
Shares Outstanding (Diluted) | 34.75M | 34.75M | 34.75M |
EPS (Basic) | n/a | n/a | -3.05 |
EPS (Diluted) | n/a | n/a | -3.05 |
EBITDA | -178.45M | -178.7M | -116.09M |
EBIT | -179.01M | -181.1M | -118.46M |
Depreciation & Amortization | 559K | 2.4M | 2.38M |
Add to Watchlist
Select watchlists to add or remove TRAX